Lubiprostone: a novel treatment for chronic constipation

Brian E Lacy, L Campbell LevySection of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USAAbstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modification...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brian E Lacy, L Campbell Levy
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/9853164e182443fb812ec360330b731b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9853164e182443fb812ec360330b731b
record_format	dspace
spelling	oai:doaj.org-article:9853164e182443fb812ec360330b731b2021-12-02T01:57:59ZLubiprostone: a novel treatment for chronic constipation1178-1998https://doaj.org/article/9853164e182443fb812ec360330b731b2008-06-01T00:00:00Zhttps://www.dovepress.com/lubiprostone-a-novel-treatment-for-chronic-constipation-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Brian E Lacy, L Campbell LevySection of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USAAbstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.Keywords: chloride, chloride channels, constipation, functional bowel disorders, gastrointestinal motility, intestinal secretion, irritable bowel syndrome, lubiprostoneBrian E LacyL Campbell LevyDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 357-364 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Brian E Lacy L Campbell Levy Lubiprostone: a novel treatment for chronic constipation
description	Brian E Lacy, L Campbell LevySection of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon NH, USAAbstract: Chronic constipation is highly prevalent, reduces patients’ quality of life, and imposes a significant health care burden on society. Lifestyle modifications and over-the-counter agents improve symptoms of constipation in some patients, however many patients have persistent symptoms and require the use of prescription medications. Three prescription medications are currently Food and Drug Administration (FDA) approved and available for the treatment of chronic constipation in adults. This review will focus on lubiprostone, the newest medication available for the treatment of chronic constipation. Lubiprostone is a bicyclic fatty acid metabolite analogue of prostaglandin E1. It activates specific chloride channels in the gastrointestinal tract to stimulate intestinal fluid secretion, increase gastrointestinal transit, and improve symptoms of constipation. This article will provide a brief overview on chloride channel function in the gastrointestinal tract, describe the structure, function, and pharmacokinetics of lubiprostone, and discuss the safety and efficacy of this new medication.Keywords: chloride, chloride channels, constipation, functional bowel disorders, gastrointestinal motility, intestinal secretion, irritable bowel syndrome, lubiprostone
format	article
author	Brian E Lacy L Campbell Levy
author_facet	Brian E Lacy L Campbell Levy
author_sort	Brian E Lacy
title	Lubiprostone: a novel treatment for chronic constipation
title_short	Lubiprostone: a novel treatment for chronic constipation
title_full	Lubiprostone: a novel treatment for chronic constipation
title_fullStr	Lubiprostone: a novel treatment for chronic constipation
title_full_unstemmed	Lubiprostone: a novel treatment for chronic constipation
title_sort	lubiprostone: a novel treatment for chronic constipation
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/9853164e182443fb812ec360330b731b
work_keys_str_mv	AT brianelacy lubiprostoneanoveltreatmentforchronicconstipation AT lcampbelllevy lubiprostoneanoveltreatmentforchronicconstipation
_version_	1718402791606583296

Lubiprostone: a novel treatment for chronic constipation

Ejemplares similares